Elisa Fabbri

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
PURPOSE The risk of febrile neutropenia (FN) in cancer patients receiving chemotherapy is mainly due to the type of chemotherapy regimen and the presence of specific risk factors in patients. The recent trend of using a dose-dense treatment schedule has enhanced the risk of FN. In the present prospective study, we evaluated the feasibility of a reduction of(More)
  • 1